Tags

Type your tag names separated by a space and hit enter

Statins: Could an old friend help in the fight against COVID-19?
Br J Pharmacol. 2020 11; 177(21):4873-4886.BJ

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain. GE-06 Pathophysiology of Renal and Vascular Damage Laboratory, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Córdoba, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain. Laboratory of Nephrology and Hypertension, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain.Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain. Laboratory of Nephrology and Hypertension, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain.Renal, Vascular and Diabetes Research Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz Universidad Autónoma, Madrid, Spain. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Fundación Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma Madrid, Madrid, Spain. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32562276

Citation

Rodrigues-Diez, Raul R., et al. "Statins: Could an Old Friend Help in the Fight Against COVID-19?" British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4873-4886.
Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020;177(21):4873-4886.
Rodrigues-Diez, R. R., Tejera-Muñoz, A., Marquez-Exposito, L., Rayego-Mateos, S., Santos Sanchez, L., Marchant, V., Tejedor Santamaria, L., Ramos, A. M., Ortiz, A., Egido, J., & Ruiz-Ortega, M. (2020). Statins: Could an old friend help in the fight against COVID-19? British Journal of Pharmacology, 177(21), 4873-4886. https://doi.org/10.1111/bph.15166
Rodrigues-Diez RR, et al. Statins: Could an Old Friend Help in the Fight Against COVID-19. Br J Pharmacol. 2020;177(21):4873-4886. PubMed PMID: 32562276.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statins: Could an old friend help in the fight against COVID-19? AU - Rodrigues-Diez,Raul R, AU - Tejera-Muñoz,Antonio, AU - Marquez-Exposito,Laura, AU - Rayego-Mateos,Sandra, AU - Santos Sanchez,Laura, AU - Marchant,Vanessa, AU - Tejedor Santamaria,Lucía, AU - Ramos,Adrian M, AU - Ortiz,Alberto, AU - Egido,Jesus, AU - Ruiz-Ortega,Marta, Y1 - 2020/07/15/ PY - 2020/05/22/received PY - 2020/06/01/revised PY - 2020/06/10/accepted PY - 2020/6/21/pubmed PY - 2020/10/28/medline PY - 2020/6/21/entrez SP - 4873 EP - 4886 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32562276/Statins:_Could_an_old_friend_help_in_the_fight_against_COVID_19 L2 - https://doi.org/10.1111/bph.15166 DB - PRIME DP - Unbound Medicine ER -